What is the 13F Pro Quality Score for LNTH?

13F Pro ranks Lantheus Holdings, Inc. (LNTH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LNTH's current score at https://13fpro.ai/research/LNTH (free sign-up required for the full ranking).

Where does 13F Pro source LNTH data?

All Lantheus Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Lantheus Holdings, Inc. files with the SEC under CIK 1521036. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LNTH in?

Lantheus Holdings, Inc. (LNTH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives LNTH's revenue?

Per Lantheus Holdings, Inc.'s latest 10-Q filed with the SEC on 2026-05-07, the biggest revenue drivers are: PYLARIFY (Oncology) ($240.9M, -6.5% YoY); DEFINITY (Cardiology) ($84.6M, +6.8% YoY); Neuraceq (Neurology) ($35.4M, +100.0% (from $0M)). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/LNTH.

What are LNTH's largest expenses?

Lantheus Holdings, Inc.'s latest 10-Q reports these as the largest expense items: Cost of goods sold ($146.4M, +8.4% YoY); Sales and marketing ($52.7M, +24.0% YoY); Research and development ($39.4M, +8.4% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is LNTH research updated on 13F Pro?

LNTH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Lantheus Holdings, Inc.(LNTH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1521036 LNTH stock profile & AI dashboard →

13F Pro Quality Score

66.9/100

Rank #495 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

58.1/100

Profitability

76.3/100

Balance Sheet

91.6/100

Earnings Quality

28.3/100

Free Cash Flow

84.7/100

Institutional Flow

45.5/100

Revenue Scale

57.6/100

Dilution Risk

24.4/100

LNTH Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Lantheus Holdings, Inc. (LNTH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LNTH at 66.9/100 on a 32-signal composite quality model, placing it at rank #495 of 2,879 stocks — the top 25% of the AI-ranked universe. LNTH scores in the top quartile across balance sheet strength (91.6), free cash flow (84.7), profitability (76.3). Areas of concern include earnings quality (28.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Lantheus Holdings, Inc. reports quarterly revenue of $377.3M, net income of $118.4M, an operating margin of 21.6%. Top institutional holders of LNTH by reported 13-F value include BlackRock,, FARALLON CAPITAL MANAGEMENT, JANUS HENDERSON GROUP PLC, based on the most recent SEC filings. LNTH trades on the Nasdaq exchange and files with the SEC under CIK 1521036. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LNTH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lantheus Holdings, Inc. directly from SEC EDGAR. Lantheus Holdings, Inc.'s 13F Pro composite quality score has ranged between 32 and 86 since 2021, currently 66.9 — an improving long-term trajectory across 30 quarterly and live scoring snapshots.

✦

Fun facts about Lantheus Holdings, Inc.

Quirks, history, and lore behind LNTH — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Annual revenue in the range of roughly $1 billion, with growth driven almost entirely by a single blockbuster diagnostic agent that took off in recent years.
3
The History
Its roots trace back to Du Pont's radiopharmaceutical division in the mid-20th century — it spent decades changing hands before emerging as an independent public company in the 2010s.
4
The Secret
It doesn't make pills or biologics — it makes radioactive tracers that light up tumors and diseased tissue inside the body, used in PET and SPECT imaging.
5
The Lore
Its star product PYLARIFY became one of the fastest-adopted prostate cancer imaging agents in history, turning a once-sleepy niche company into a Wall Street darling almost overnight.
6
The Giveaway
The leading U.S. supplier of radiopharmaceutical diagnostics, best known for PYLARIFY — the PSMA PET scan tracer that's reshaping how doctors find and stage prostate cancer.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving LNTH's Business? Latest 10-Q Breakdown

AI-extracted from Lantheus Holdings, Inc.'s 10-Q filed 2026-05-07 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q1 revenue $377.3M (+1.2% YoY) driven by Neuraceq contribution post-Lantheus Biosciences acquisition and DEFINITY growth, offset by PYLARIFY pricing pressure; net income $118.4M (+62% YoY) boosted by $59.3M SPECT business sale gain.

Biggest Revenue Drivers

Total revenue: $377.3M+1.2% YoY

PYLARIFY (Oncology)$240.9M-6.5% YoY

Decreased due to lower net sales price in 2026, partially offset by increased sales volume.

DEFINITY (Cardiology)$84.6M+6.8% YoY

Increased from higher sales volume.

Neuraceq (Neurology)$35.4M+100.0% (from $0M)

New contribution following Lantheus Biosciences acquisition in July 2025; no comparable prior-year revenue.

Strategic Partnerships and Other$16.3M+52.1% YoY

Increased from CDMO revenue generated post-Evergreen Therapeutics acquisition and MK-6240 investigational use revenue.

Largest Expense Items

Cost of goods sold$146.4M+8.4% YoY

Increased due to lower PYLARIFY net sales price, higher intangible asset amortization from Lantheus Biosciences acquisition, and SPECT business sale, partially offset by Neuraceq gross profit.

Sales and marketing$52.7M+24.0% YoY

Increased due to employee-related costs for Neuraceq sales and marketing expenditures for PYLARIFY TruVu launch preparation.

Research and development$39.4M+8.4% YoY

Increased from impacts of Lantheus Biosciences and Evergreen acquisitions and LNTH-2403 project costs, partially offset by lower regulatory payments compared to prior year.

General and administrative$57.5M+1.3% YoY

Increased modestly due to acquisition integration costs, offset by reduced litigation costs and legal settlement received in Q1 2026.

Watch Items from the Filing

PYLARIFY revenue declined 6.5% YoY to $240.9M due to net sales price reductions effective January 1, 2025, when CMS transitioned from transitional pass-through payment to mean unit cost methodology; competitive PSMA agents retain higher TPT Status payments.
LNTH-2501 NDA review extended to June 29, 2026 from March 29, 2026 for manufacturing-related information review; FDA tentative approval of PNT2003 ANDA received March 2, 2026 but subject to 30-month Hatch-Waxman stay and ongoing patent litigation.
Company received $59.3M gain on SPECT business sale to Illuminated but future consideration includes unsecured $20M seller note, $20M deferred cash (or $25M if unpaid by Jan 1, 2030), and contingent payments up to $30M based on unachieved revenue milestones.
Significant contingent liabilities from acquisitions: Evergreen up to $727.5M in milestone payments; Lantheus Biosciences up to $400M earn-out/milestone payments on Neuraceq sales plus $30M to Piramal based on earnings metrics.
Advanced Accelerator Applications (Novartis) patent infringement litigation over PNT2003 ANDA pending court decision as of filing date; putative securities class action consolidated in Southern District of New York with amended complaint filed March 13, 2026 alleging false statements regarding business performance.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$377.3M

Net Income

Q1 2026

$118.4M

Free Cash Flow

Q1 2026

$125.1M

Operating Margin

Q1 2026

21.6%

D/E Ratio

Q1 2026

0.47

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+0.5% YoY

$1.54BFY 2025

FY22 $935.1MFY23 $1.30BFY24 $1.53BFY25 $1.54B

Net Income

-25.2% YoY

$233.6MFY 2025

FY22 $28.1MFY23 $326.7MFY24 $312.4MFY25 $233.6M

Operating Income

-32.0% YoY

$310.8MFY 2025

FY22 $36.2MFY23 $364.6MFY24 $457.0MFY25 $310.8M

EPS (Diluted)

-21.8% YoY

$3.41FY 2025

FY22 $0.40FY23 $4.65FY24 $4.36FY25 $3.41

Total Assets

+12.5% YoY

$2.23BFY 2025

FY22 $1.32BFY23 $1.65BFY24 $1.98BFY25 $2.23B

Total Debt

+0.5% YoY

$570.2MFY 2025

FY22 $558.4MFY23 $563.3MFY24 $567.2MFY25 $570.2M

Op. Cash Flow

-28.4% YoY

$390.1MFY 2025

FY22 $281.8MFY23 $305.3MFY24 $544.8MFY25 $390.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.54B +0.5%	$1.53B +18.3%	$1.30B +38.6%	$935.1M +119.9%	$425.2M +25.3%	$339.4M
Net Income	$233.6M -25.2%	$312.4M -4.4%	$326.7M +1063.9%	$28.1M +139.4%	$-71.3M -429.1%	$-13.5M
Operating Income	$310.8M -32.0%	$457.0M +25.3%	$364.6M +907.4%	$36.2M +159.5%	$-60.8M -1348.9%	$-4.2M
EPS (Diluted)	$3.41 -21.8%	$4.36 -6.2%	$4.65 +1062.5%	$0.40 +137.7%	$-1.06 -324.0%	$-0.25
Total Assets	$2.23B +12.5%	$1.98B +19.9%	$1.65B +25.0%	$1.32B +53.0%	$863.8M -0.7%	$869.8M
Total Debt	$570.2M +0.5%	$567.2M +0.7%	$563.3M +0.9%	$558.4M +199.6%	$186.4M -22.0%	$239.1M
Operating Cash Flow	$390.1M -28.4%	$544.8M +78.5%	$305.3M +8.3%	$281.8M +422.6%	$53.9M +228.8%	$16.4M

AI Insight: LNTH Financial Trends

Operating income has more than halved from its Q3 2024 peak of $134M to $81M in Q1 2026, signaling meaningful margin compression despite stable revenues.

• Operating income collapsed from $134M in Q3 2024 to $44M in Q3 2025, recovering only partially to $81M in Q1 2026.

• Revenue has been range-bound between $373M and $407M across all eight quarters, showing no meaningful growth trajectory.

• Operating cash flow rebounded to $125M in Q1 2026, the strongest reading since Q3 2024's $175M, a modest positive signal.

• Total debt has remained stable near $568–$571M since Q1 2025, following a spike to $1,130M in Q3 2024 that quickly reversed.

⚠ Operating margin has trended sharply lower — op income fell from $134M to $44M peak-to-trough — watch for sustained recovery above $100M.

⚠ Net income is highly volatile, swinging from -$12M in Q4 2024 to $131M in Q3 2024; below-the-line items warrant scrutiny.

⚠ Equity ticked up to $1,212M in Q1 2026, a six-quarter high, partly reflecting the strong net income print — monitor for consistency.

AI Insight: LNTH Ratio Trends

Profitability rebounded sharply in Q1 2026 on NPM and ROE, but ROIC continues to compress, now at 18.2% versus a 27.5% peak in Q4 2024.

• NPM surged to 31.4% in Q1 2026, the highest single-quarter reading in the dataset, recovering strongly from the Q3 2025 trough of 7.2%.

• Operating margin has trended down from 35.3% in Q3 2024 to 21.6% in Q1 2026, with Q3 2025 hitting a multi-quarter low of 11.4%.

• ROIC declined from 27.5% in Q4 2024 to 18.2% in Q1 2026, a 9.3pp contraction over five quarters.

• Leverage improved modestly; D/E fell from 0.96 in Q3 2024 to 0.47 in Q1 2026, the lowest level in the dataset.

⚠ ROIC compression to 18.2% in Q1 2026 despite the NPM spike warrants scrutiny — capital efficiency is deteriorating even as earnings appear strong.

⚠ The Q3 2025 operating margin collapse to 11.4% suggests potential cost or volume volatility; monitor whether Q1 2026 recovery is structural or seasonal.

⚠ Q4 2024 NPM of -3.0% and negative ROE/ROA point to a large one-off charge; confirm no recurrence in upcoming periods.

Get alerted when LNTH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Lantheus Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LNTH

BlackRock, Inc.
$620.7M8,183,193 sh
FARALLON CAPITAL MANAGEMENT LLC
$423.5M5,583,479 sh
JANUS HENDERSON GROUP PLC
$362.2M4,774,841 sh
FMR LLC
$350.9M4,626,453 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$240.8M3,174,274 sh
VANGUARD CAPITAL MANAGEMENT LLC
$221.1M2,914,314 sh
STATE STREET CORP
$184.3M2,429,803 sh
AMERICAN CENTURY COMPANIES INC
$135.1M1,781,106 sh
GEODE CAPITAL MANAGEMENT, LLC
$134.0M1,765,952 sh
MORGAN STANLEY
$124.9M1,646,463 sh

Fund	Value	Shares
BlackRock, Inc.	$620.7M	8,183,193
FARALLON CAPITAL MANAGEMENT LLC	$423.5M	5,583,479
JANUS HENDERSON GROUP PLC	$362.2M	4,774,841
FMR LLC	$350.9M	4,626,453
VANGUARD PORTFOLIO MANAGEMENT LLC	$240.8M	3,174,274
VANGUARD CAPITAL MANAGEMENT LLC	$221.1M	2,914,314
STATE STREET CORP	$184.3M	2,429,803
AMERICAN CENTURY COMPANIES INC	$135.1M	1,781,106
GEODE CAPITAL MANAGEMENT, LLC	$134.0M	1,765,952
MORGAN STANLEY	$124.9M	1,646,463

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LNTH on your watchlist

Track score changes the day Lantheus Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LNTH a good stock to buy?

13F Pro's AI-powered analysis of Lantheus Holdings, Inc. (LNTH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LNTH are available on the LNTH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LNTH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LNTH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Lantheus Holdings, Inc.'s investment landscape.